GlaxoSmithKline PLC (GSK) Position Lowered by AE Wealth Management LLC

AE Wealth Management LLC lowered its stake in GlaxoSmithKline PLC (NYSE:GSK) by 5.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 30,193 shares of the pharmaceutical company’s stock after selling 1,767 shares during the period. AE Wealth Management LLC’s holdings in GlaxoSmithKline PLC were worth $1,226,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC grew its position in GlaxoSmithKline PLC by 46.3% in the first quarter. Geode Capital Management LLC now owns 129,145 shares of the pharmaceutical company’s stock valued at $5,444,000 after acquiring an additional 40,858 shares during the last quarter. Bank of Montreal Can grew its position in GlaxoSmithKline PLC by 19.5% in the second quarter. Bank of Montreal Can now owns 153,200 shares of the pharmaceutical company’s stock valued at $6,607,000 after acquiring an additional 24,962 shares during the last quarter. Ledyard National Bank grew its position in GlaxoSmithKline PLC by 6.3% in the second quarter. Ledyard National Bank now owns 10,362 shares of the pharmaceutical company’s stock valued at $447,000 after acquiring an additional 610 shares during the last quarter. Eqis Capital Management Inc. grew its position in GlaxoSmithKline PLC by 18.4% in the second quarter. Eqis Capital Management Inc. now owns 28,716 shares of the pharmaceutical company’s stock valued at $1,238,000 after acquiring an additional 4,461 shares during the last quarter. Finally, First National Bank of Omaha grew its position in GlaxoSmithKline PLC by 0.3% in the second quarter. First National Bank of Omaha now owns 19,177 shares of the pharmaceutical company’s stock valued at $827,000 after acquiring an additional 57 shares during the last quarter. Institutional investors own 9.84% of the company’s stock.

GlaxoSmithKline PLC (NYSE GSK) traded down $0.13 during trading hours on Monday, hitting $35.06. The stock had a trading volume of 2,585,200 shares, compared to its average volume of 3,439,725. The company has a market capitalization of $85,170.00, a PE ratio of 12.43, a P/E/G ratio of 1.94 and a beta of 1.00. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. GlaxoSmithKline PLC has a 52 week low of $34.72 and a 52 week high of $44.53.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be paid a $0.5037 dividend. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.75%. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline PLC’s payout ratio is currently 157.94%.

In related news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were bought at an average cost of $14.00 per share, with a total value of $5,999,994.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.00% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline PLC (GSK) Position Lowered by AE Wealth Management LLC” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/20/glaxosmithkline-plc-gsk-position-lowered-by-ae-wealth-management-llc.html.

A number of research firms have issued reports on GSK. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, September 21st. BidaskClub cut GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. TheStreet cut GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Citigroup Inc. reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 27th. Finally, Investec cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $44.33.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply